New drug TAK-360 tested for Long-Term safety in sleep disorders
NCT ID NCT07646678
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking the drug. The main goal is to see how well people tolerate TAK-360 over many months and to track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-360
What this could lead to
If successful, this could confirm that TAK-360 is safe enough to use long-term for managing excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia.
What could go wrong
This is an extension study focused on safety, not on proving how well the drug works. It may not show clear benefits, and side effects could emerge over longer use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Site 1
RECRUITINGShinjuku-ku, Tokyo, 162-0851, Japan